Plasma Derived Medicinal Products
We are tackling the global supply and demand problem of plasma medicines, using our unique Australian invention which challenges an 80 year industry status quo.
A Revolution in Technology
Plasma Fractionation
Aegros has invented a unique process called Haemafrac® that fractionates human plasma into specialty medicinal proteins. These proteins – including immunoglobulin, hyperimmune globulins, and albumin = are well-established and highly effective medicines for numerous serious medical conditions including treating immunodeficiency, cancers, infectious diseases, serious inflammatory disorders, and autoimmmune diseased.
Worldwide, Plasma is a very scarce and precious resource – and the current, growing demand of plasma medicines significantly outstrips supply. This imbalance directly results in chronic shortages of life-saving plasma medicines – meaning patients are often unable to access the treatments they desperately need. Imagine what could be possible if this shortage could be solved? Click here to find out more
Hyperimmune Production
Hyperimmune globulins
Hyperimmune Globulins are mostly specialty antibodies that fight infection or modulate immune function. Manufacturing them requires a specialised process to “hyper-concentrate” specific antibodies with high purity. Using Haemafrac® technology Aegros can produce these products at much lower cost and at very high purity.
With its unique fractionation process, Haemafrac® changes everything.
Engineering and Plasma Producing
Do it or have it done
Aegros is both an Engineering and a Biopharmaceutical company. We work with governments, health systems, patient groups and blood collection partners to design and build exceptional quality fractionation programs. With Haemafrac® Aegros can truly transform the economics, sustainability, and quality of antiquated or inefficient fractionation programs around the world.
